within Pharmacolibrary.Drugs.ATC.A;

model A02AC01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 3.3333333333333335e-07,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A02AC01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Calcium carbonate is an inorganic compound commonly used as a dietary calcium supplement or antacid. It is approved for use in the treatment and prevention of calcium deficiency, osteoporosis, and as an adjunct therapy for conditions that benefit from increased calcium intake. It is widely available over the counter and is considered safe when used as directed.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult individuals from secondary sources; limited clinical PK studies due to its poor systemic absorption.</p><h4>References</h4><ol><li><p>Straub, DA (2007). Calcium supplementation in clinical practice: a review of forms, doses, and indications. <i>Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition</i> 22(3) 286–296. DOI:<a href=\"https://doi.org/10.1177/0115426507022003286\">10.1177/0115426507022003286</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17507729/\">https://pubmed.ncbi.nlm.nih.gov/17507729</a></p></li><li><p>Tawbi, HA, et al., &amp; Beumer, JH (2013). Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. <i>Cancer chemotherapy and pharmacology</i> 72(5) 1143–1147. DOI:<a href=\"https://doi.org/10.1007/s00280-013-2283-x\">10.1007/s00280-013-2283-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24036846/\">https://pubmed.ncbi.nlm.nih.gov/24036846</a></p></li><li><p>Katsube, T, et al., &amp; Kano, T (2019). Effects of Food and Calcium Carbonate on the Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist. <i>Clinical therapeutics</i> 41(9) 1747–1754.e2. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2019.06.004\">10.1016/j.clinthera.2019.06.004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31303281/\">https://pubmed.ncbi.nlm.nih.gov/31303281</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A02AC01;
